Vor Biopharma Inc.
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hemato…
Biotechnology
US, Cambridge [HQ]
Document Reader
Link Index · Filing Reader · 10K/10QThis analysis tool lets you read the documents of Vor Biopharma Inc.
DEF 14-A Proxies
10-Ks
10-Qs
Not a single 10-Q doc.
LDA 1/2s
Click To Read:
DEF 14-A Proxies
Not a single DEF 14-A proxy doc.
10-K Filings
Not a single 10-K doc.
10-Q Filings
Not a single 10-Q doc.
LDA 1/2 Filings [Lobbying]
Not a single LDA doc.